272 related articles for article (PubMed ID: 26566079)
1. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
Amaravadi RK; Schilder RJ; Martin LP; Levin M; Graham MA; Weng DE; Adjei AA
Mol Cancer Ther; 2015 Nov; 14(11):2569-75. PubMed ID: 26333381
[TBL] [Abstract][Full Text] [Related]
3. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
[TBL] [Abstract][Full Text] [Related]
5. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.
Liu H; Liao R; He K; Zhu X; Li P; Gong J
Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
[TBL] [Abstract][Full Text] [Related]
8. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
[TBL] [Abstract][Full Text] [Related]
9. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Crim A; Rowland M; Ruskin R; Dvorak J; Greenwade M; Walter A; Gillen J; Ding K; Moore K; Gunderson C
Gynecol Oncol; 2017 Aug; 146(2):268-272. PubMed ID: 28583323
[TBL] [Abstract][Full Text] [Related]
11. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
[TBL] [Abstract][Full Text] [Related]
12. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
13. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
14. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC
J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425
[TBL] [Abstract][Full Text] [Related]
16. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo.
Morrish E; Mackiewicz L; Silke N; Pellegrini M; Silke J; Brumatti G; Ebert G
Viruses; 2020 Aug; 12(8):. PubMed ID: 32824616
[TBL] [Abstract][Full Text] [Related]
19. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C
Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
